Akanda (AKAN) Liabilities and Shareholders Equity (2020 - 2025)
Akanda (AKAN) posted quarterly Liabilities and Shareholders Equity of $6.2 million for Q4 2025, down 21.71% year-over-year from $7.9 million in Q4 2024, and little changed quarter-over-quarter from $6.2 million in Q2 2025.
Akanda (AKAN) Liabilities and Shareholders Equity (2020 - 2025) Analysis & Trends
Akanda's Liabilities and Shareholders Equity history runs 6 years deep, the most recent figure standing at $6.2 million for Q4 2025.
- In Q4 2025, Liabilities and Shareholders Equity fell 21.71% year-over-year to $6.2 million; the TTM figure through Dec 2025 stood at $30.3 million (down 55.34% YoY), while the FY2025 annual figure was $6.2 million, down 21.71% from the prior year.
- Liabilities and Shareholders Equity for Q4 2025 stood at $6.2 million, roughly flat from $6.2 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $43.5 million in Q2 2022, with the low at $6.2 million in Q4 2025.
- The 5-year median for Liabilities and Shareholders Equity is $9.4 million (2023), against an average of $20.5 million.
- The sharpest annual moves came in 2022 and 2023: Liabilities and Shareholders Equity jumped 384.67% in 2022, then sank 77.33% in 2023.
- Akanda's Liabilities and Shareholders Equity stood at $8.0 million in 2021, then surged by 384.67% to $39.0 million in 2022, then tumbled by 77.33% to $8.8 million in 2023, then slipped by 10.47% to $7.9 million in 2024, then slipped by 21.71% to $6.2 million in 2025.
- Business Quant data shows AKAN's Liabilities and Shareholders Equity at $6.2 million in Q4 2025, $6.2 million in Q2 2025, and $7.9 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | 6.18 Bn |
| 10 | Akanda | 261,906.86 | 261,906.86 | - | 6.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 6.20 Mn |
| Jun 30, 2025 | 6.22 Mn |
| Dec 31, 2024 | 7.91 Mn |
| Jun 30, 2024 | 9.97 Mn |
| Dec 31, 2023 | 8.84 Mn |
| Jun 30, 2023 | 41.10 Mn |
| Dec 31, 2022 | 39.00 Mn |
| Jun 30, 2022 | 43.48 Mn |
| Dec 31, 2021 | 8.05 Mn |
| Jun 30, 2021 | 34.16 Mn |
| Dec 31, 2020 | 4.27 Mn |